Neutralization of the SARS-CoV-2 Mu Variant by Convalescent and Vaccine Serum

Cited by (201)

Items 101–200 of 201

1. Clinical and genomic signatures of SARS-CoV-2 Delta breakthrough infections in New York
   Ralf Duerr, Dacia Dimartino, Christian Marier, Paul Zappile, Samuel Levine, Fritz François, Eduardo Iturrate, Guiqing Wang, Meike Dittmann, Jennifer Lighter et al. · 2022 · EBioMedicine
2. A Recent SARS-CoV-2 Infection Enhances Antibody-Dependent Cellular Cytotoxicity against Several Omicron Subvariants following a Fourth mRNA Vaccine Dose
   Guillaume Beaudoin-Bussières, Alexandra Tauzin, Katrina Dionne, Gabrielle Gendron‐Lepage, Halima Medjahed, Josée Perreault, Inès Levade, Laila Alfadhli, Yuxia Bo, Renée Bazin et al. · 2023 · Viruses
3. Determination of the factors responsible for the tropism of SARS-CoV-2-related bat coronaviruses to Rhinolophus bat ACE2
   Shigeru Fujita, Yusuke Kosugi, Izumi Kimura, Kenzo Tokunaga, Jumpei Ito, Kei Sato, Keita Matsuno, Naganori Nao, Hirofumi Sawa, Shinya Tanaka et al. · 2023 · Journal of Virology
4. Multiple mutations of SARS-CoV-2 Omicron BA.2 variant orchestrate its virological characteristics
   Izumi Kimura, Daichi Yamasoba, Hesham Nasser, Hayato Ito, Jiří Zahradník, Jiaqi Wu, Shigeru Fujita, Keiya Uriu, Jiei Sasaki, Tomokazu Tamura et al. · 2023 · Journal of Virology
5. Virological characteristics of a SARS-CoV-2-related bat coronavirus, BANAL-20-236
   Shigeru Fujita, Arnon Plianchaisuk, Sayaka Deguchi, Hayato Ito, Naganori Nao, Lei Wang, Hesham Nasser, Tomokazu Tamura, Izumi Kimura, Yukie Kashima et al. · 2024 · EBioMedicine
6. SARS-CoV-2 Virology
   Yijia Li, Jonathan Z. Li · 2022 · Infectious Disease Clinics of North America
7. Additional mutations based on Omicron BA.2.75 mediate its further evasion from broadly neutralizing antibodies
   Huimin Guo, Jie Jiang, Senlin Shen, Xiangyang Ge, Qing Fan, Bing Zhou, Lin Cheng, Bin Ju, Zheng Zhang · 2023 · iScience
8. Finger stick blood test to assess postvaccination SARS‐CoV ‐2 neutralizing antibody response against variants
   Sing Mei Lim, Hoi Lok Cheng, Huan Jia, Patthara Kongsuphol, Bhuvaneshwari D O Shunmuganathan, Ming Wei Chen, Say Yong Ng, Xiaohong Gao, Shuvan Prashant Turaga, Sascha Pierre Heussler et al. · 2022 · Bioengineering & Translational Medicine
9. A SARS-CoV-2: Companion Animal Transmission and Variants Classification
   Rachana Pandit, Qiana L. Matthews · 2023 · Pathogens
10. High-Throughput Molecular Dynamics-Based Alchemical Free Energy Calculations for Predicting the Binding Free Energy Change Associated with the Selected Omicron Mutations in the Spike Receptor-Binding Domain of SARS-CoV-2
    Rajendra N. Bhadane, Outi M. H. Salo‐Ahen · 2022 · Biomedicines
11. Caveats on COVID-19 herd immunity threshold: the Spain case
    David García‐García, Enrique Morales, Eva S. Fonfría, Isabel Vigo, César Bordehore · 2022 · Scientific Reports
12. Antigenicity of the Mu (B.1.621) and A.2.5 SARS-CoV-2 Spikes
    Debashree Chatterjee, Alexandra Tauzin, Annemarie Laumaea, Shang Yu Gong, Yuxia Bo, Aurélie Guilbault, Guillaume Goyette, Catherine Bourassa, Gabrielle Gendron‐Lepage, Halima Medjahed et al. · 2022 · Viruses
13. Assessment of the Biological Impact of SARS-CoV-2 Genetic Variation Using an Authentic Virus Neutralisation Assay with Convalescent Plasma, Vaccinee Sera, and Standard Reagents
    Naomi S. Coombes, Kevin R. Bewley, Yann Le Duff, Matthew Hurley, Lauren J. Smith, Thomas M. Weldon, Karen L. Osman, Steven T. Pullan, Neil J. Berry, Bassam Hallis et al. · 2023 · Viruses
14. Epidemiology and analysis of SARS-CoV-2 Omicron subvariants BA.1 and 2 in Taiwan
    Li‐Teh Liu, Shyh‐Shin Chiou, Po‐Chih Chen, Chun‐Hong Chen, Ping‐Chang Lin, Ching‐Yi Tsai, Wan‐Long Chuang, Shang‐Jyh Hwang, Inn‐Wen Chong, Jih‐Jin Tsai · 2023 · Scientific Reports
15. An Antigenic Space Framework for Understanding Antibody Escape of SARS-CoV-2 Variants
    Nathaniel L. Miller, Thomas Clark, Rahul Raman, Ram Sasisekharan · 2021 · Viruses
16. A Strategy to Detect Emerging Non-Delta SARS-CoV-2 Variants with a Monoclonal Antibody Specific for the N501 Spike Residue
    Rama Devudu Puligedda, Fetweh H. Al‐Saleem, Christoph Wirblich, Chandana Devi Kattala, Marko Jović, Laura Geiszler, Himani Devabhaktuni, Giora Feuerstein, Matthias J. Schnell, M. Sack et al. · 2021 · Diagnostics
17. Cross-reactive humoral and CD4+ T cell responses to Mu and Gamma SARS-CoV-2 variants in a Colombian population
    Fabiola Martel, Juliana Cuervo-Rojas, Juana Ángel, Beatríz Ariza, John Mario González, Carolina Ramírez-Santana, Yeny Acosta‐Ampudia, Luisa Fernanda Murcia-Soriano, Norma Montoya, Claudia Cecilia Cardozo-Romero et al. · 2023 · Frontiers in Immunology
18. Characterization of intrinsic and effective fitness changes caused by temporarily fixed mutations in the SARS-CoV-2 spike E484 epitope and identification of an epistatic precondition for the evolution of E484A in variant Omicron
    Simon Schröder, Anja M. Richter, Talitha Veith, Jackson Emanuel, Luca Gudermann, Kirstin Friedmann, Lara Maria Jeworowski, Barbara Mühlemann, Terry C. Jones, Marcel A. Müller et al. · 2023 · Virology Journal
19. Immune response and reactogenicity after immunization with two-doses of an experimental COVID-19 vaccine (CVnCOV) followed by a third-fourth shot with a standard mRNA vaccine (BNT162b2): RescueVacs multicenter cohort study
    Ana Ascaso-del-Rio, Javier García‐Pérez, Mayte Pérez‐Olmeda, Eunate Arana‐Arri, Itziar Vergara, Carla Pérez-Ingidua, Mercedes Bermejo, María Castillo de la Osa, Natale Imaz-Ayo, Ioana Riaño Fernández et al. · 2022 · EClinicalMedicine
20. Strategies to tackle SARS-CoV-2 Mu, a newly classified variant of interest likely to resist currently available COVID-19 vaccines
    Md. Jamal Hossain, Ali Ahmed Rabaan, Abbas Saleh Al Mutair, Saad Alhumaid, Talha Bin Emran, Gutulla Saikumar, Saikat Mitra, Kuldeep Dhama · 2022 · Human Vaccines & Immunotherapeutics
21. Detecting SARS-CoV-2 neutralizing immunity: highlighting the potential of split nanoluciferase technology
    Sundararaj Stanleyraj Jeremiah, Kei Miyakawa, Akihide Ryo · 2022 · Journal of Molecular Cell Biology
22. Comparative Analysis of Vaccine-Induced Neutralizing Antibodies against the Alpha, Beta, Delta, and Omicron Variants of SARS-CoV-2
    Philipp Girl, Heiner von Buttlar, Enrico Mantel, Markus H. Antwerpen, Roman Wölfel, Katharina Müller · 2024 · Vaccines
23. Epidemiological Dynamics of SARS-CoV-2 Variants During Social Protests in Cali, Colombia
    Luz Helena Patiño, Sergio Castañeda, Marina Muñoz, Nathalia Ballesteros, Angie Ramírez, Nicolás Luna, Enzo Guerrero-Araya, Julie Pérez, Camilo A. Correa‐Cárdenas, María Clara Duque et al. · 2022 · Frontiers in Medicine
24. Breakthrough infections by SARS-CoV-2 variants boost cross-reactive hybrid immune responses in mRNA-vaccinated Golden Syrian hamsters
    Juan García-Bernalt Diego, Gagandeep Singh, Sonia Jangra, Kim Handrejk, Manon Laporte, Lauren A. Chang, Sara S. El Zahed, Lars Pache, Max W. Chang, Prajakta Warang et al. · 2024 · PLoS Pathogens
25. SARS-CoV-2 and the Vaccination Hype
    Piero Sangaletti, Jane Doe, Antonietta Morena Gatti, Clemens G. Arvay, Livio Giuliani, Herbert Lettner · 2022 · International Journal of Vaccine Theory Practice and Research
26. Commentary: Face masks in physical education classes during the COVID-19 delta variant wave: a call for awareness
    Andrew Sortwell, Rodrigo Ramírez‐Campillo, Jorge Knijnik, Pedro Miguel Forte, Daniel Almeida Marinho, Ricardo Manuel Pires Ferraz, Kevin Trimble · 2021 · German Journal of Exercise and Sport Research
27. Therapeutic Status of Famotidine in COVID-19 Patients: A Review
    Moein Mohseni, Vahid Raissi, Yasamin Sharifan, Kimia Barikro, Sasan Amiri, Maedeh Sadat Mohseni, Farid Raeisi, Kimia Masoumi, Sina Khodakarami, Omid Raiesi · 2022 · Infectious Disorders - Drug Targets
28. The Efficiency of Convalescent Plasma Therapy in the Management of Critically Ill Patients Infected With COVID-19: A Matched Cohort Study
    Chun Pan, Hui Chen, Jianfeng Xie, Yingzi Huang, Yi Yang, Bin Du, Haibo Qiu · 2022 · Frontiers in Medicine
29. The SARS‐CoV‐2 Mu variant should not be left aside: It warrants attention for its immuno‐escaping ability
    Stefano Pascarella, Martina Bianchi, Marta Giovanetti, Daniele Narzi, Roberto Cauda, Antonio Cassone, Massimo Ciccozzi · 2022 · Journal of Medical Virology
30. Real-world clinical outcomes of treatment with casirivimab-imdevimab among patients with mild-to-moderate coronavirus disease 2019 during the Delta variant pandemic
    Yasuhito Suzuki, Yoko Shibata, Hiroyuki Minemura, Takefumi Nikaido, Yoshinori Tanino, Atsuro Fukuhara, Ryuzo Kanno, Hiroyuki Saito, Shuzo Suzuki, Taeko Ishii et al. · 2022 · International Journal of Medical Sciences
31. The SARS-CoV-2 Variants and their Impacts
    Amir Muhaimin Akmal Shukri, Seok Mui Wang, Suet Lin Chia, Siti Farah Alwani Mohd Nawi · 2022 · Journal of Pure and Applied Microbiology
32. Continuous mutation of SARS-CoV-2 during migration via three routes at the beginning of the pandemic
    Tomokazu Konishi · 2022 · PeerJ
33. SARS-CoV-2 variants C.1.2 and B.1.621 (Mu) partially evade neutralization by antibodies elicited upon infection or vaccination
    Prerna Arora, Amy Madeleine Kempf, Inga Nehlmeier, Luise Graichen, Martin Sebastian Winkler, Martin Lier, Sebastian R. Schulz, Hans‐Martin Jäck, Anne Cossmann, Metodi V. Stankov et al. · 2022 · Cell Reports
34. Effectiveness of Naturally Acquired and Vaccine-Induced Immune Responses to SARS-CoV-2 Mu Variant
    Edmilson Ferreira de Oliveira-Filho, Bladimiro Rincón‐Orozco, Nathalia Andrea Jones-Cifuentes, Brigitte Ofelia Peña-López, Barbara Mühlemann, Christian Drosten, Andrés Moreira‐Soto, Jan Felix Drexler · 2022 · Emerging infectious diseases
35. Prevalence of side-effects associated with the booster dose of Pfizer-BioNTech (BNT162b2) of COVID-19 Vaccine among vaccinated adults in the Eastern province of Saudi Arabia
    Jenan Ahmed Al-Matouq, Mohammad Daud Ali, Samiah Mohammad Al-Somali, Ayaz Ahmad, Nuzhat Banu, Munfis Patel · 2022 · Infection Prevention in Practice
36. Nanocell COVID-19 vaccine triggers a novel immune response pathway producing high-affinity antibodies which neutralize all variants of concern
    Steven Y. Gao, Nancy B. Amaro-Mugridge, Jocelyn Madrid-Weiss, Nikolina Petkovic, Natasha Vanegas, Kumar Visvanathan, Bryan R.G. Williams, Jennifer A. MacDiarmid, Himanshu N. Brahmbhatt · 2023 · Frontiers in Immunology
37. Hamsters Protected from SARS-CoV-2 Delta Variant Challenge after Two Doses of Adjuvanted SARS-CoV-2 Recombinant Spike Protein (S-2P) and One Dose of Beta S-2P
    Tsun‐Yung Kuo, Chia-En Lien, Yi‐Jiun Lin, Meei‐Yun Lin, Chung-Chin Wu, Wei-Hsuan Tang, John D. Campbell, Paula Traquina, Ya-Shan Chuang, Luke Tzu-Chi Liu et al. · 2022 · The Journal of Infectious Diseases
38. Respiratory Virus Infections during the COVID-19 Pandemic Revealed by Multiplex PCR Testing in Japan
    Sho Yamashita, Satoshi Ikegame, Keita Nakatomi, Yuko Sakurai, Hiroe Shuto, Noriko Sato, Yoshihiro Mizoguchi, M Uehara, Nobutaka Nakashima, Isamu Okamoto et al. · 2023 · Microbiology Spectrum
39. Molecular recognition of SARS-CoV-2 spike protein with three essential partners: exploring possible immune escape mechanisms of viral mutants
    Yan Cheng, Dan Zheng, Derong Zhang, Du Guo, Yueteng Wang, Wei Yong Liu, Li Liang, Jianping Hu, Hubing Shi, Ting Luo · 2023 · Journal of Molecular Modeling
40. Household Secondary Transmission of the Severe Acute Respiratory Syndrome Coronavirus 2 Alpha Variant From a Community Cluster in a Nursery in Japan
    Tatsuki Ikuse, Yuta Aizawa, Yugo Shobukawa, Nobuko Tomiyama, Hitoshi Nakayama, Masako Takahashi, Kensuke Muto, Satoshi Hasegawa, Masashi Takahashi, Miyako Kon et al. · 2022 · The Pediatric Infectious Disease Journal
41. Prototype and BA.5 protein nanoparticle vaccines protect against Omicron BA.5 variant in Syrian hamsters
    Traci L. Bricker, Astha Joshi, Nadia Soudani, Suzanne M. Scheaffer, Nita Patel, Mimi Guebre‐Xabier, Gale Smith, Michael Diamond, Adrianus C. M. Boon · 2024 · Journal of Virology
42. Review of Novel Corona Virus Disease (Covid-19) in India
    Ghanshyam Sevak, Yashpal Singh Chauhan, Narendra Parihar, Mahendra Singh Rathore · 2022 · Research Journal of Pharmacology and Pharmacodynamics
43. Insights into the limited global spread of the immune evasive SARS-CoV-2 variant Mu
    Mary E. Petrone, Carolina Gonçalves de Oliveira Lucas, Bridget L. Menasché, Mallery I. Breban, Inci B. Yildirim, Melissa Campbell, Saad B. Omer, Albert Icksang Ko, Nathan D. Grubaugh, Akiko Iwasaki et al. · 2022 · medRxiv
44. Structural Analysis of the SARS ‐ CoV ‐2 Spike N‐Terminal Domain Across Wild‐Type and Recent Variants: A Comparative Study
    Miriana Quaranta, Allegra Via, Stefano Pascarella · 2025 · Proteins Structure Function and Bioinformatics
45. Comparison between Neutralization Capacity of Antibodies Elicited by COVID-19 Natural Infection and Vaccination in Indonesia: A Prospective Cohort
    Sitti Nurisyah, Mitsuhiro Iyori, Ammar Abdurrahman Hasyim, Akihiko Sakamoto, Hinata Hashimoto, Kyouhei Yamagata, Saya Yamauchi, Khaeriah Amru, Kartika Hardianti Zainal, Irfan Idris et al. · 2023 · Antibodies
46. SARS-CoV-2 vaccine challenge based on spike glycoprotein against several new variants
    Rike Syahniar, Dayu Swasti Kharisma · 2022 · Clinical and Experimental Vaccine Research
47. Development and external validation of the DOAT and DOATS scores: simple decision support tools to identify disease progression among nonelderly patients with mild/moderate COVID-19
    Yoko Shibata, Hiroyuki Minemura, Yasuhito Suzuki, Takefumi Nikaido, Yoshinori Tanino, Atsuro Fukuhara, Ryuzo Kanno, Hiroyuki Saito, Shuzo Suzuki, Taeko Ishii et al. · 2023 · BMC Pulmonary Medicine
48. Neutralization of Different Variants of SARS-CoV-2 by a F(ab′)2 Preparation from Sera of Horses Immunized with the Viral Receptor Binding Domain
    Mariajosé Rodríguez, Mariana del Valle Cepeda, Carlos Bello, Miguel Angel Lopez, Yoneira Fabiola Sulbarán, Carmen Luisa Loureiro, Ferdinando Liprandi, Rossana Celeste Jaspe, Hector Rafael Rangel, Flor Helene Pujol · 2023 · Antibodies
49. Review of Clinical Trials of COVID-19 Vaccination Booster in SARS-CoV-2 Variants Era: To Take It or Not To Take It
    Zhipeng Yan, Ming Yang, Ching‐Lung Lai · 2022 · Frontiers in Drug Discovery
50. Neutralizing Antibody Responses Elicited by Inactivated Whole Virus and Genetic Vaccines against Dominant SARS-CoV-2 Variants during the Four Epidemic Peaks of COVID-19 in Colombia
    Diego Alejandro Álvarez-Díaz, Ana Luisa Muñoz, María T. Herrera-Sepúlveda, Pilar Tavera-Rodríguez, Katherine Laiton‐Donato, Carlos Franco-Muñoz, Héctor Alejandro Ruiz-Moreno, Marisol Galindo, Jenssy D. Catama, Andrea Bermúdez-Forero et al. · 2022 · Vaccines
51. Whole-Genome Comparison of Representatives of All Variants of SARS-CoV-2, Including Subvariant BA.2 and the GKA Clade
    Ida Bagus Kade Suardana, Bayu Krisna Mahardika, Made Pharmawati, Putu Henrywaesa Sudipa, Tri Komala Sari, Nyoman B. Mahendra, Gusti Ngurah Mahardika · 2023 · Advances in Virology
52. Cross-neutralization ability of anti-MERS-CoV monoclonal antibodies against a variety of merbecoviruses
    Lin Pan, Yu Kaku, Jarel Elgin Tolentino, Yusuke Kosugi, Kei Sato · 2025 · Frontiers in Microbiology
53. Genomic, socio-environmental, and sequencing capability patterns in the surveillance of SARS-CoV-2 in Latin America and the Caribbean up to 2023
    Macarena Concha-Toloza, Luis Collado González, Alfredo Herrera‐Estrella, Darío Fernández Do Porto, Rebeca Campos-Sánchez, José Arturo Molina-Mora · 2025 · Scientific Reports
54. In silico prediction of immune-escaping hot spots for future COVID-19 vaccine design
    Sing‐Han Huang, Yi-Ting Chen, Xiang-Yu Lin, Yi-Yi Ly, Ssu-Ting Lien, Pei-Hsin Chen, Cheng-Tang Wang, Suh‐Chin Wu, Chwen-Cheng Chen, Ching‐Yung Lin · 2023 · Scientific Reports
55. High-Affinity Neutralizing DNA Aptamers against SARS-CoV-2 Spike Protein Variants
    Mohamad Ammar Ayass, Natalya Griko, Victor Pashkov, Trivendra Tripathi, Wanying Cao, Nazanin Javan, Jun Dai, Jin Zhang, Kevin Zhu, Lina Abi-Mosleh · 2023 · COVID
56. COVID-19 Acceleration and Vaccine Status in France - Summer 2021
    Christelle Baunez, Mickaël Degoulet, Stéphane Luchini, Patrick A Pintus, Miriam Teschl · 2021 · SSRN Electronic Journal
57. Predicting SARS-CoV-2-specific CD4+ and CD8+ T-cell responses elicited by inactivated vaccines in healthy adults using machine learning models
    Jie Ning, Yayi Ren, Zelin Zhang, Xianhuang Zeng, Qinjin Wang, Jia Xie, Yue Xu, Yali Fan, Huilan Li, Aixia Zhai et al. · 2025 · Clinical and Experimental Medicine
58. Description of Symptoms Caused by the Infection of the SARS-CoV-2 B.1.621 (Mu) Variant in Patients With Complete CoronaVac Vaccination Scheme: First Case Report From Santiago of Chile
    Carlos Barrera‐Avalos, Roberto Luraschi, Claudio Acuña‐Castillo, Mabel Vidal, Andrea Mella‐Torres, Ailén Inostroza-Molina, Rodrigo Vera, Sergio Vargas, Iván Hernández, Christian Perez et al. · 2022 · Frontiers in Public Health
59. Mu SARS‐CoV‐2 (B.1.621) variant: A genomic snapshot across the Colombian‐Venezuelan border
    Luz Helena Patiño, Nathalia Ballesteros, Marina Muñoz, Angie Ramírez, Nicolás Luna, Sergio Castañeda, Reinaldo Gutiérrez-Marín, Jesús Alberto Mendoza-Ibarra, Raúl Rodríguez, Diana Patricia Bohada et al. · 2023 · Journal of Medical Virology
60. Phylogenetic analysis of SARS-CoV-2 viruses circulating in the South American region: Genetic relations and vaccine strain match
    Paula Perbolianachis, Diego Ferla, Rodrigo Arce, Irene Ferreiro, Alicia Costábile, Mercedes Paz, Diego Simón, Pilar Moreno, Juan Cristina · 2022 · Virus Research
61. Infección por SARS-CoV-2 y respuesta de anticuerpos a la vacuna BNT162b2 en trabajadores de la salud de primera línea de atención para covid-19
    Norma Cecilia Serrano, Doris Cristina Quintero-Lesmes, Claudia C. Colmenares-Mejía, Isail Salazar Acosta, Diana Paola Suárez Suárez, Ligia Meneses, Olga Lucía Sopó-Rincón, Andrea Milena Guatibonza, Bladimiro Rincón‐Orozco · 2022 · Medicina
62. Nonsystematic Reporting Biases of the SARS-CoV-2 Variant Mu Could Impact Our Understanding of the Epidemiological Dynamics of Emerging Variants
    Mary E. Petrone, Carolina Gonçalves de Oliveira Lucas, Bridget L. Menasché, Mallery I. Breban, Inci B. Yildirim, Melissa Campbell, Saad B. Omer, Edward Charles Holmes, Albert Icksang Ko, Nathan D. Grubaugh et al. · 2023 · Genome Biology and Evolution
63. Early signals of Omicron severity in sentinel UK hospitals
    Shazaad S. Y. Ahmad, Benjamin C. Brown, André Charlett, Emma Ann Davies, Thomas House, Ben Kirkman, Nicholas W. Machin, Robert O'Hara, Rob Paton, Lorenzo Pellis et al. · 2021 · Research Square
64. Low-Dose Interferon I and III-Based Nasal Sprays: A Good-Looking COVID-19 Vaccine Candidate and a Therapy of the Future?
    Theodor-Nicolae Carp, Michael Metoudi, Brent Brown, Vanshika Ojha · 2023 · Preprints.org
65. Deep mutational scanning of whole SARS-CoV-2 spike in an inverted infection system
    Shunta Taminishi, Songling Li, Yusuke Higuchi, Yuhei Kirita, Daisuke Motooka, Yuki Ozaki, Takao Arimori, Nariko Ikemura, Yumi Itoh, Satoaki Matoba et al. · 2023 · bioRxiv (Cold Spring Harbor Laboratory)
66. Inferring variant-specific effective reproduction numbers from combined case and sequencing data
    Marlin D Figgins, Trevor Bedford · 2025 · eLife
67. SARS-CoV-2 Vaccinated Breakthrough Infections With Fatal and Critical Outcomes in the Department of Antioquia, Colombia
    Andres Cardona, Simón Villegas, Maria Stella Lopez, Maria Angelica Maya, Celeny Ortiz-Restrepo, Olga Hernandez-Ortiz, Karl Ciuoderis, Laura Pérez, Idabely Betancour, Carolina Muñoz et al. · 2022 · Research Square
68. A SARS-CoV-2 variant-induced NTD-targeting antibody enhances viral infection via a distinctive binding mode
    Wenting Li, C Liu, Yaning Li, Qi Gui, Lin Cheng, Qing Fan, Bing Zhou, Haiyan Wang, Xiangyang Ge, Zheng Zhang et al. · 2026 · PLoS Pathogens
69. The effects of the COVID-19 pandemic on airline ground operations
    Henrricco Nieves Pujol Tucci, Geraldo Cardoso de Oliveira Neto · 2022 · Aeronautics and Aerospace Open Access Journal
70. A Parallel Algorithm for Designing Primer and Probe for Accurate Detection of Severe Acute Respiratory Syndrome Coronavirus
    Hilal Arslan, Rıza Durmaz · 2023 · Black Sea Journal of Engineering and Science
71. Pros and Cons for COVID-19 Vaccination and Boost of Young Adults in Light of Recent Literature
    John J. Nemunaitis, Paul Lehmann, James C. Willey · 2022 · Medical Research Archives
72. Safety and Immunogenicity of Heterologous Boost Immunisation With an Aerosolized Ad5-nCoV After Two-Dose Priming With an Inactivated SARS-CoV-2 Vaccine CoronaVac in Adults: A Randomised, Open-Label, Parallel-Control Trial
    Jingxin Li, Shipo Wu, Xiling Guo, Rong Tang, Baoying Huang, Xiaoqin Chen, Hai-Tao Huang, Yin Chen, Lihua Hou, Jin-Bo Gou et al. · 2022 · SSRN Electronic Journal
73. Immunity Escape of SARS-CoV-2 Variants: Omicron Leads the Way
    Rupali Dhingra, Aarjoo Sharma, Sanjeev Balda, Anshika Billa, Shiv Nandan Sah, Neena Capalash, Prince Sharma · 2022 · Preprints.org
74. Neutralizing responses in fully vaccinated with BNT162b2, CoronaVac, ChAdOx1, and Ad26.COV2.S against SARS-CoV-2 lineages in Colombia, 2020-2021
    Diego Alejandro Álvarez-Díaz, Ana Luisa Muñoz, María T. Herrera-Sepúlveda, Pilar Tavera-Rodríguez, Katherine Laiton‐Donato, Carlos Franco-Muñoz, Héctor Alejandro Ruiz-Moreno, Dioselina Peláez‐Carvajal, Alejandra M. Muñoz-Suarez, Marisol Galindo et al. · 2022 · medRxiv
75. Nanocell COVID-19 vaccine elicits iNKT-licensed dendritic cells to produce high affinity antibodies neutralizing Variants of Concern
    Steven Y. Gao, Nancy B. Amaro-Mugridge, Jocelyn Madrid-Weiss, Nikolina Petkovic, Natasha Vanegas, Kumar Visvanathan, Vinod Ganju, Gavin M. Marx, Bryan R.G. Williams, Jennifer A. MacDiarmid et al. · 2022 · Research Square
76. Low-Dose Interferon I and III-Based Nasal Sprays: A Good-Looking COVID-19 Vaccine Candidate?
    Theodor-Nicolae Carp, Michael Metoudi · 2022 · Preprints.org
77. Antigenic Map of SARS-CoV-2 Variants Including Omicron
    Yuki Furuse · 2021 · SSRN Electronic Journal
78. Variants of the Novel Coronavirus
    Sayan Bhattacharyya, Amitabha Dan, Dipak Pal · 2022 · Journal of Clinical Case Reports and Studies
79. Peer Review #2 of "Continuous mutation of SARS-CoV-2 during migration via three routes at the beginning of the pandemic (v0.1)"
    2022 · PeerJ
80. Peer Review #1 of "Continuous mutation of SARS-CoV-2 during migration via three routes at the beginning of the pandemic (v0.1)"
    2022 · PeerJ
81. Peer Review #2 of "Continuous mutation of SARS-CoV-2 during migration via three routes at the beginning of the pandemic (v0.2)"
    2022 · PeerJ
82. Whole-genome comparison of representatives of all variants of SARS-CoV-2, including subvariant BA.2 and the GKA clade
    Ida Bagus Kade Suardana, Bayu Krisna Mahardika, Made Pharmawati, Putu Henrywaesa Sudipa, Tri Komala Sari, Gusti Ngurah Mahardika · 2022 · Research Square
83. mRNA-1273 and Ad26.COV2.S Vaccines Protect Against the B.1.621 Variant of SARS-CoV-2
    Tamarand L. Darling, Baoling Ying, Bradley M. Whitener, Laura A. VanBlargan, Traci L. Bricker, Chieh-Yu Liang, Astha Joshi, Gayan Bamunuarachchi, Kuljeet Seehra, Aaron J. Schmitz et al. · 2022 · SSRN Electronic Journal
84. Robust models of disease heterogeneity and control, with application to the SARS-CoV-2 epidemic
    Kory D. Johnson, Annemarie Grass, Daniel Toneian, Mathias Beiglböck, Jitka Polechová · 2022 · PLOS Global Public Health
85. Impacto de la variante de interés Mu en la pandemia de COVID-19 en Colombia
    Brigitte Ofelia Peña-López, María Carolina Velásquez-Martínez, Bladimiro Rincón‐Orozco · 2022 · Salud UIS
86. Local monitoring of SARS-CoV-2 variants in two large California counties in 2021
    Noah Kojima, Eugenia M. Khorosheva, Lauren Lopez, Mikhail H. Hanewich-Hollatz, J. Cesar Ignacio‐Espinoza, Matthew Brobeck, Janet Chen, Matthew I. Geluz, Victoria Hess, Sophia Quasem et al. · 2022 · Scientific Reports
87. Importancia de la vigilancia genómica de SARS-CoV-2 en los tiempos de las vacunas contra la COVID-19
    Nathalia Andrea Jones-Cifuentes, Brigitte Ofelia Peña-López, Bladimiro Rincón‐Orozco · 2022 · Salud UIS
88. Low-Dose Interferon I and Iii-Based Nasal Sprays: A Good-Looking Covid-19 Vaccine Candidate?
    Theodor-Nicolae Carp, Michael Metoudi · 2022 · Preprints.org
89. Low-Dose Interferon I and III-Based Nasal Sprays: A Good-Looking COVID-19 Vaccine Candidate?
    Theodor-Nicolae Carp, Michael Metoudi, Brent Brown, Vanshika Ojha · 2023 · Preprints.org
90. SARS-CoV-2 Phylointeractomics Reveal Functional Evolution of Its Variants Across Susceptible Human Organs
    Xu Li, Peihan Wu, Danqi Bao, Zhihao Guo, Hua Jiang, Yue Sui, Weixiang Bian, Shuai Wang, Fa Zhang, Jianbo Wu et al. · 2024 · Research Square
91. 2) Virus Research on COVID-19
    Kei Sato · 2023 · Nihon Naika Gakkai Zasshi
92. COVID-19 in Latin America: Tracking the SARS-CoV-2 Mu (B.1.621) Variant: Epidemiology, Genomics, and Vaccine Resistance
    Angie Ramírez, Luz Helena Patiño, Sergio Castañeda, Nicolás Luna, Nathalia Ballesteros, Marina Muñoz, Alberto E. Paniz-Mondolfi, Juan David Ramírez · 2024 · The Latin American studies book series
93. Emergence of SARS-CoV-2 Omicron lineages shifted antibody-mediated protection curves
    David Pattinson, Joshua G. Petrie, Peter J. Jester, Lizheng Guan, Jennifer P. King, Peter Halfmann, Edward A. Belongia, Huong Q. Nguyen, Yoshihiro Kawaoka, Gabriele Neumann · 2025 · iScience
94. Reviewer #1 (Public review): Inferring variant-specific effective reproduction numbers from combined case and sequencing data
    2025 · eLife
95. eLife Assessment: Inferring variant-specific effective reproduction numbers from combined case and sequencing data
    Eduardo Luis Franco · 2025 · eLife
96. Inferring variant-specific effective reproduction numbers from combined case and sequencing data
    Marlin D Figgins, Trevor Bedford · 2025 · eLife
97. Systems virology as a cornerstone for pandemic responsiveness: A G2P-Japan perspective
    Kei Sato · 2025 · Cell Host & Microbe
98. Additional file 1 of Characterization of intrinsic and effective fitness changes caused by temporarily fixed mutations in the SARS-CoV-2 spike E484 epitope and identification of an epistatic precondition for the evolution of E484A in variant Omicron
    Simon Schröder, Richter, Anja, Veith, Talitha, Jackson Emanuel, Luca Gudermann, Kirstin Friedmann, Lara Maria Jeworowski, Barbara Mühlemann, Terry C. Jones, Marcel A. Müller et al. · 2024 · Figshare
99. Additional file 1 of Real-world effectiveness and factors associated with effectiveness of inactivated SARS-CoV-2 vaccines: a systematic review and meta-regression analysis
    Xu, Shiyao, Li, Jincheng, Wang, Hongyuan, Wang, Fuzhen, Yin, Zundong, Zhifeng Wang · 2023 · Figshare
100. Infection-Simulator, Immunostimulatory and Immunomodulatory Effects of Interferons I and III in Biological Systems: A New Era in Vaccinology and Therapeutics Possible?
     Theodor-Nicolae Carp, Michael Metoudi, Vanshika Ojha · 2026 · Preprints.org